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ABSTRACT 
Objective: To analyze the incidence of adverse drug reactions (ADRs) associated with chemotherapeutic drugs and study its management.  
Methods: A prospective observational study was carried out on hospitalized patients undergoing cancer chemotherapy. The identified ADRs were 
assessed for causality, severity and preventability.  
Results: Among 120 patients followed 100 patients developed 161 ADRs. Most common ADRs were anemia, leucopenia, mucositis fever, and chills. As 
per the WHO causality assessment 87(54.0%) ADRs were probable whereas with the Naranjo’s scale 98(60.9%) were probable. Moderate reactions 
were 59.62%. Majority 122 (75.8%) of the ADRs were not preventable. Most of ADRs were implicated with cisplatin followed by 5-Fluro-uracil and the 
combination drugs which included FAC (Flurouracil, adriyamycin, cyclophosphamide) regimen, Paclitaxel, and Carboplatin (PC) regimen.  
Conclusion: Patients undergoing cancer chemotherapy have higher chances to develop ADRs. Those patients on chemotherapy with cisplatin 
followed by 5-Fu and combination drugs which include FAC and PC regimen should be strictly monitored for the early detection and prompt 
management of the ADR to prevent morbidity and mortality. 
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Drugs are widely used because of their ability to effect the biological 
systems of the body. The use of these drugs may also carry certain 
unwanted or unintended effects. Each time a patient is exposed to a 
drug we cannot be certain about the unwanted effects of the 
product. However, we can learn from previous experience where 
patients have been exposed to the similar drug. ADR is recognized as 
a hazard of drug therapy. It may develop promptly or only after 
prolonged medication or even after stoppage of the suspected drug. 
The World Health Organization defines an ADR as “any reaction that 
is noxious and unintended and occurs at a dose normally used in 
man for diagnosis, prophylaxis and treatment of diseases or for 
modification of physiological function”[1].  
Cancer has become a global burden because of the aging, increased 
adoption of cancer-causing behaviors particularly smoking and 
exposure to triggering factors like chemicals, radiations, unhealthy 
eating habits and a sedentary lifestyle. Different modalities for 
treatment of cancer include radiation, surgery, chemotherapy, 
hormonal therapy, immunotherapy, biologic therapy and 
cryosurgery [2]. The treatments with cancer chemotherapeutic 
drugs are often associated with a variety of serious and non-serious 
ADRs. The most common side effect of chemotherapy administration 
is nausea with or without vomiting, diarrhea, alopecia, darkening of 
skin and nails, darkening of the injection site, myelosuppression, 
mucositis, gonadal dysfunction, hyper-uricemia, neuropathy, 
cardiomyopathy, hemorrhagic cystitis, impaired renal function, 
electrolyte imbalance, etc [3].  
The objectives of ADR monitoring include detection of unknown 
drug-related safety problems, identification, and quantification of 
risk factors associated with the use of drugs and prevention of 
patients from being affected unnecessarily. The information 
pertaining to ADRs can be used to formulate therapeutic guidelines, 
public health policy decision and in pharmacoeconomic research. 
Based on these facts the regulatory authorities can bring about 
changes in package inserts and restrict the use of drugs or withdraw 
drugs from the market [2]. The analysis of ADRs associated with the 
cancer chemotherapy in a hospital set up gives an insight regarding 
the causality, severity, and preventability of the identified ADRs. It 
may also create awareness among the treating physicians. This can 
prevent future occurrence of similar ADRs in the same patient. 
Hence, this study was undertaken to analyze the ADRs identified in 
an oncology unit of a tertiary care teaching hospital. 
A prospective observational study was carried out in the oncology 
department of Justice K S Hegde Charitable Hospital at Mangalore 
over a period of eight months. A total of 120 patients were enrolled 
in the study. All hospitalized patients of age 18 y and above and who 
were on cancer chemotherapy were included in the study. Patients 
using an alternative system of medicine such as ayurveda and 
homeopathy, subjects being treated as out-patient and mentally 
challenged subjects were excluded from the study. The study was 
approved by the central ethics committee of Nitte University Ref No: 
NU/CEC/P. G.-03/2015. During the study period, the in-patients of 
the oncology ward diagnosed with all types of cancer and treated 
with all types of chemotherapeutic drugs were observed on a daily 
basis. When an ADR was suspected information regarding patients 
demographics, diagnosis, drug therapy, relevant investigational 
reports were collected and documented in a suitably designed 
patient data collection form and ADR reporting form after obtaining 
the informed consent. It was then discussed with the treating 
physician for detailed evaluation. Once the ADR is confirmed it was 
analyzed for causality using WHO probability scale and Narajo’s 
algorithm. The severity was analyzed by using Hartwigs severity 
scale, and preventability was assessed by using Modified Shomock 
and Thoronton scale. The management of the identified ADR was 
studied. The outcome of the ADR was then documented. Data 
analysis was carried out using statistical package for social sciences 
(SPSS) 16.0. Descriptive statistics was applied for analysing the 
collected data. 
Among 120 cancer patients followed 58 (48.3%) male and 62 
(51.7%) female received chemotherapy for a duration of eight 
months. A Hundred patients developed a total of 161 ADRs out of 
which 54(54%) were female, and 46 (46%) were male. This shows 
that incidence of ADRs was more common in female patients. The 
prevalence of cancer in the age group of 50-59 was found to be 
higher 42(35%). Highest distribution pattern of cancer among the 
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patients were found to be carcinoma of breast 28(23.3%) followed 
by buccal mucosa 13(10.83%), ovary 12(10.0%), tongue 8(6.6%), 
stomach 8(6.6%), cervix 7(5.83%), oropharynx 7(5.83%), glottis 
7(5.83%), colon-rectal 7(5.83%), esophagus 6(5.0%), lung 
5(4.16%), lymphoma 4(3.33%), pancreas 3(2.5%), alveolus 
3(2.5%) and testis 2(1.6%). Out of 120 patients who received 
chemotherapy 43(35.08%) patients were administered with 
Cisplatin followed by FAC 25 (20.8%), PC 19(15.8%), 5-FU 
11(9.2%), CHOP 6(4.2%). details of chemotherapy regimen is 
provide in table 1. 
 
Table 1: Pattern of chemotherapy regimen prescribed 
Chemotherapy regimen Frequency Percentage 
Cispltin 43 35.8 
5Fluro uracil+Adriyamycin+Cyclophosphamide (FAC) 25 20.8 
Paclitaxel+Carboplatin 19 15.8 
5-Flurouracil (5-Fu)+Leucoverin 11 9.2 
Cyclophosphamide+Doxorubicin+Vincristine+Prednisone(CHOP) 6 4.2 
Oxaliplatin+Capecetabine 5 4.1 
Carboplatin 3 2.5 
Paclitaxel 3 2.5 
Adriyamycin+cyclophosphamide (AC) 1 0.8 
Doxorubicin 1 0.8 
Cisplatin+Etoposide 1 0.8 
Epirubicin+Oxaliplatin 1 0.8 
Cyclophosphamide+Adriyamycin+Vincristine 1 0.8 
5-Flurouracil+Cyclophosphamide+Methotrexate 1 0.8 
Total 120 100 
 A total of 161(83.33%) ADRs were observed in patients receiving chemotherapy. Adverse effect on the hematological system was more commonly seen in 
patients 61(37.88%) followed by gastrointestinal effects 44 (27.32%), central nervous system and peripheral nervous system 16(9.93%). Refer table 2. 
 
Table 2: Identified ADRs and organ system affected 
Organ system involved Adverse drug reaction Frequency Percentage 
Blood Anemia 34 21.1 
Leucopenia 20 12.4 
Neutropenia 2 1.2 
Thrombocytopenia 3 3.1 
Thrombocytosis 2 1.2 
Cardiovascular system Hypotension 4 2.5 
CNS and PNS Fever and chills 7 4.3 
Headache 6 3.7 
Tingling and numbness 3 1.9 
Gastrointestinal system Anorexia 4 2.5 
Constipation 6 3.7 
Diarrhea 4 2.5 
Fatigue 2 1.2 
Heartburn 3 1.9 
Mouth sore 4 2.5 
Mucositis 11 6.8 
Nausea 4 2.5 
Vomiting 6 3.7 
Musculoskeletal system Limb edema 1 0.6 
Muscle and joint pain 6 3.7 
Renal system Hyperuricemia 4 2.5 
Hypokalemia 3 1.9 
Hypocalcaemia 2 1.2 
Hypomagnesaemia 1 0.6 
Hypervolemia 1 0.6 
Respiratory system Cough 6 3.7 
Skin and appendages Itching 2 1.2 
Nail discoloration 4 3.1 
Skin color changes 5 3.1 
Sensory system Tinnitus 1 0.6 
Total no of ADRs  161 100 
Cisplatin 63(39.1%) was the most commonly prescribed individual class of drug and found to be the cause of most of the ADRs occurred when 
compared to other class of individual and combination drugs. Refer fig. 1. 
 
The causality assessment of reported ADRs was done using WHO 
UMC Scale and Naranjo’s algorithm. WHO UMC Scale revealed that 
majority of the ADRs were probable 87 (54.0%) followed by 
possible 48(29.8%), certain 21(13.0), and unlikely 5(3.1%). 
Naranjo’s algorithm showed that majority of the ADRs were 
probable 98(60.9%), followed by possible 50(31.1%), definite 
9(5.6%), and doubtful 4(2.5%).  
The severity level was assessed using Hart wig severity scale 
according to which 96(59.2%) ADR were moderate, 67(41.61%) 
were mild and 2(1.2%) were found to be severe, no fatal reactions 
were reported in the study. As per the Modified Shumock and 
Thornton preventability scale 122(75.8%) reactions were not 
preventable, 31(19.3%) were probably preventable and 8(5.0%) 
were definitely preventable. 
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Fig. 1: ADRs caused by chemotherapy regimen 
 
The ADRs were managed by different approaches to reduce the severity 
level, 63.35% of the ADRs were managed by providing additional 
treatments without making any changes in the drug regimen, 38.04% 
ADRs were managed with no additional treatment and in the case of 
13.04% ADRs the chemotherapy was post ponded due to the severity of 
the ADR. Specific treatment was given to 40.4% patients, symptomatic 
treatment to 36% of patients and 23.6% of patients did not receive any 
drug therapy for the ADRs. Refer table 3. 
Different classes of drugs were used for the management of each 
ADR. Filagristin, blood transfusion and iron preparations which 
were given to increase the blood count. Septilin was given as an 
immunomodulator, loperamide for diarrhoea, normal saline and 
parenteral preparation of potassium and calcium chloride for the 
management of electrolyte imbalance.  
Acetaminophen, mefenamic acid, and diclofenac sodium were 
prescribed for pain management. Vitamin B complex and 
multivitamin tablets were used for the symptomatic relief of 
anorexia, tingling, and numbness. Aluminum hydroxide, 
magnesium hydroxide, itopride, and sucralfate were used to treat 
gastric ulcers. 
 
Table: 3 Management of the identified ADRs 
Management Frequency Percentage (%) 
Pattern of drug therapy for the identified ADRs   
Specific 65 40.4 
Symptomatic 58 36.0 
Nil 38 23.6 
Management of ADR   
No change in drug regimen but additional treatment was given 122 75.77 
Drug withdrawn/Chemo post ponded 21 13.04 
No change in drug regimen and no additional treatment 18 11.18 
Outcome of ADR Management   
Recovery 133 81.40 
Continuing 24 14.90 
Unknown 6 3.7 
 
The current study analyzed the adverse drug reactions due to cancer 
chemotherapeutic agents. The incidence of ADRs in our hospital 
during the study period was 83.33%. This is comparable to study 
conducted in a tertiary care teaching hospital in eastern India by 
Prasad et al. [7] where they reported an incidence of 86.53%. In the 
current study hematological system was most commonly affected 
61(37.88%) because of the non-selective action of chemotherapeutic 
drugs. They target the rapidly dividing cells of bone marrow along 
with the tumor cells which eventually causes bone marrow 
suppression leading to anemia, leucopenia, neutropenia and 
thrombocytopenia.  
This finding is consistent with the study conducted by Khandelwal et 
al. [5] But it is in contrast with the study conducted by Poddar et al. 
[7] wherein gastrointestinal system was most commonly affected. 
Adverse drug reactions such as nausea and vomiting were less 
reported in the present study since it was well managed with 
adequate pre-medication. Parenteral dexamethasone, ranitidine, and 
ondansetron before chemotherapy and daily 3 doses of ondansetron 
were given orally for three consecutive days to the patient for 
preventing early and late stage emesis after the chemotherapy. It is 
clear from this that it is easy to predict a known ADR and therefore 
measures can be taken to prevent the same.  
Cisplatin, carboplatin, paclitaxel, doxorubicin, and cyclo-
phosphamide were more commonly associated with adverse drug 
reactions because its act primarily in rapidly dividing tissues such as 
bone marrow, gastrointestinal tract, mucosal cells and reproductive 
system. This finding is similar to the study carried out by Goyal et al. 
[3] and Prasad et al. [7] According to WHO causality assessment 
scales most of the reported ADRs were probable (54.0%). This 
finding is in contrast to the study conducted by Goyal et al. [3] in 
which ADRs belonged to the category possible (39.0%). Causality 
assessment of adverse effect was also done utilizing the Naranjo’s 
scale where 60.9% ADRs was found to be probable, 31.1% were 
possible, and 5.6% were definite. This finding was similar to the 
study carried out by Prasad et al. [7]. 
As per Hartwig SC et. al severity scale 59.62% ADRs were moderate 
followed by mild (41.61%) and severe (1.2%). This finding is in 
consonance with the study conducted by Khandelwal et al. [5] 
wherein 47.77% were moderate followed by mild and severe 
reactions. The findings of 5.0% ADRs being definitely preventable 
followed by 19.3% of probably preventable was comparable with 
the results of a study by Khandelwal et al. [5] where 81.1% were not 
preventable followed by 18.0% of probably preventable reactions. 
The management strategy resulted in an outcome of complete 
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recovery in 81.40% of patients whereas 14.91% of patients did not 
recover from the ADRs. The outcomes of 6 ADRs were unknown due 
to the unavailability of complete data of the patients because of their 
immediate discharge after chemotherapy.  
This study provides baselines characteristics of ADRs due to cancer 
chemotherapy. The incidence of adverse drug reaction associated 
with the chemotherapeutic agent was found to be higher as it has a 
narrow therapeutic index. These ADRs can be minimized by early 
detection, reducing drug toxicity, modifying the doses or drug 
regimens that implicate adverse effect. The study report states that 
when patients have chemotherapy with individual drugs, especially, 
Cisplatin, 5-Fluro uracil and combination drug regimens which 
include FAC, CHOP, and PC they should be strictly and continuously 
monitored for the symptoms of ADRs. The results of this study 
highlight the importance of monitoring the in patients on cancer 
chemotherapy for any signs of ADRs. The early detection and 
prompt management of these ADRs can reduce its health-related 
and economic effects on the patients. We observed that these 
patients and their family members required good counseling 
regarding the adverse effects of the cancer chemotherapy. In many 
cases alopecia, skin and nail discolouration, loss of appetite caused a 
lot of frustration and emotional instability among the patients and 
their bystanders. The study had some limitations like the small 
sample size and short duration. The ADRs were monitored manually 
the electronic reporting of ADRs could have generated more reports 
from the ward physicians and nurses. 
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